Several in vitro and in vivo results have expanded the role of these molecules from potentiating glucose-stimulated insulin secretion to promoting -cell survival under different stressful environments by favoring proliferation, neogenesis and resistance to apoptosis ( via secretion of IGF-2 from the same cells ( In agreement with experimental studies, GLP-1 analogues, particularly liraglutide, sustain the maintenance of -cell function in obese individuals with early T2D, and these effects are presumably independent of weight loss ( Further, experimental data suggest that the pro-survival action of GLP-1RAs may also be mediated by the Akt-dependent stimulation of the mTORC1/S6K1 pathway, the activation of which is dependent upon the IGF-1R, as observed in rodent islet cells ( in vitro , exendin-4 lost the ability to activate this pathway, suggesting that GLP-1 analogues may restore -cell proliferation via autocrine or paracrine activation of IGF-1R ( In concert, these results define a new scenario of action for incretin-based therapy that may involve the adipo-insular axis, linking the weight lowering competence with the sustained protection of -cells from diabetogenic stressors
Over time, researchers noticed additional benefits that went well beyond glucose management, including reductions in inflammatory markers and improvements in heart health indicators
Novo Nordisk has commenced the filing of legal actions in the US against certain medical spas, weight loss or wellness clinics, and compounding pharmacies to cease and desist from false advertising, trademark infringement and/or unlawful sales of non-FDA approved compounded products claiming to contain semaglutide
Results are reported as the median (IQR) or mean (s.d.)
Sleep disruption could inhibit the drugs actions as well, as poor sleep is shown to delay the release of the bodys natural GLP-1 hormone
While this works fine for calorie control, it is terrible for protein distribution
